ALK and non-small cell lung carcinoma: We have previously shown that inhibition of MET signaling either with the small-molecule MET and ALK inhibitor crizotinib or by RNA interference targeted to MET mRNA resulted in marked antitumor effects in MET amplification–positive NSCLC cell lines both in vitro and in vivo (21).